Subscribe To
acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — acrivon Therapeutics, Inc. (“...
September 19, 2023, 8:32 pm
acrivon: precision-testing your trial patients before enrolment
ACRV has a platform that tests trial patients for sensitivity to a tested drug before enrolling them. This way, it aims to make phase 2 trials more ef...
March 26, 2023, 9:53 am
acrivon therapeutics to present at the oppenheimer 33rd annual healthcare conference
WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- acrivon Therapeutics, Inc. (“...
March 6, 2023, 8:00 am
acrivon therapeutics announces pricing of initial public offering
WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — acrivon Therapeutics, Inc. (“...
November 15, 2022, 3:16 am